Glacier Peak Capital’s Novo Nordisk NVO Stock Holding History

Glacier Peak Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-80,000	Closed	-$2.04M	–	88
2019 Q2	$2.04M	Buy	+80,000	New	+$1.98M	1.93%	16

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Glacier Peak Capital's NVO Position: Q3 2019 in Review

Glacier Peak Capital sold out of Novo Nordisk (NVO) in Q3 2019, closing a stake of 80,000 shares — an estimated $2.04M sold.

Glacier Peak Capital first reported a position in NVO in Q2 2019 and held it in 1 quarter. The position peaked at $2.04M in Q2 2019. 564 funds tracked by Wall St. Rank hold NVO as of Q3 2019.

Glacier Peak Capital reported no remaining Novo Nordisk position as of Q3 2019 after selling out during the quarter.
Glacier Peak Capital sold 80,000 Novo Nordisk shares in Q3 2019, an estimated $2.04M.
Glacier Peak Capital first reported a position in Novo Nordisk in Q2 2019 and held it in 1 quarter.
Glacier Peak Capital's Novo Nordisk position peaked at $2.04M in Q2 2019.
564 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2019.

Based on Glacier Peak Capital's 13F filing for Q3 2019, filed 12 Nov 2019.